Beam Therapeutics Inc. Equity-NMS: BEAM

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$31.88

52W high :

$73.27

EPS(TTM): :

-4.46

Shares O/S :

76.22 M

Market cap :

2.43 B

What is the share price of Beam Therapeutics Inc. today?

Beam Therapeutics Inc. (BEAM) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Beam Therapeutics Inc.?

Yes, Indian Investors can invest in the Beam Therapeutics Inc. (BEAM) Share by opening an international trading account with Angel One.

How can I purchase Beam Therapeutics Inc. shares in India?

Purchasing Beam Therapeutics Inc. (BEAM) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Beam Therapeutics Inc. (BEAM) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Beam Therapeutics Inc.?

Yes, you can purchase fractional shares of Beam Therapeutics Inc. (BEAM) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Beam Therapeutics Inc.?

The market capitalization of Beam Therapeutics Inc. on January 1, 1970, is $0.

What documents are required to invest in Beam Therapeutics Inc. stocks?

In order to invest in Beam Therapeutics Inc. (BEAM) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Beam Therapeutics Inc. is a biotechnology company engaged in providing life-long cures to patients suffering from serious diseases. The Company operates a fully integrated platform for precision genetic medicines. Its base editing technology enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). The Company is advancing its base editing technology across three disease-area portfolios: hematology, immunology/oncology and genetic diseases. Its clinical-stage programs include BEAM-101, BEAM-201, BEAM-301 and BEAM-302. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy designed to offer a profile, incorporating base edits that are intended to mimic single nucleotide polymorphisms seen in individuals with hereditary persistence of fetal hemoglobin (HPFH). BEAM-201 is a development candidate comprised of T cells.